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Abstract
Background: Oral anticoagulants (OAC) are recommended in all patients with atrial fibrillation (AF) 
after thromboembolic events without contraindications. It is hypothesized herein, that the majority of pa-
tients with AF after thromboembolic events receive OAC and the presence of specific factors, predisposes 
the use of non-vitamin K antagonist oral anticoagulants (NOACs).
Methods: This is a retrospective study, encompassing patients with AF hospitalized in a reference 
cardiology center over the years 2014–2017. Thromboembolic events were defined as: ischemic stroke, 
transient ischemic attack and systemic embolism. Inclusion criteria were the following: diagnosis of 
non-valvular AF at discharge from hospital, hospitalization not resulting in death. 
Results: Among 2834 hospitalized patients with AF, a history of thromboembolic events was identified 
in 347 (12.2%) patients. In the group studied, of 347 patients with AF after a thromboembolic event, 
322 (92.8%) received OAC, including 133 patients on vitamin K antagonist (41.3% of patients on 
OAC) and 189 patients on NOACs (58.7% of patients on OAC). Among patients treated with NOACs 
the majority were on dabigatran (116 patients, 61.4%), followed by rivaroxaban (54 patients, 28.6%), 
and apixaban (19 patients, 10%). Multivariate logistic regression analysis demonstrated that the pres-
ence of arterial hypertension reduced the chance for NOACs use (odds ratio [OR] 0.4, 95% confidence 
interval [CI] 0.2–0.9, p = 0.04) and left atrial size ≤ 40 mm was a factor increasing the chance for the 
use of NOACs (OR 2.5, 95% CI 1.1–5.8, p = 0.03).
Conclusions: Nearly all hospitalized patients with AF received OAC in the secondary prevention of 
thromboembolic complications. NOACs were used for secondary prevention of stroke among patients 
with AF in patients with fewer comorbidities. (Cardiol J XXXX; XX, X: xx–xx)
Key words: atrial fibrillation, oral anticoagulants, secondary prevention, thromboembolic 
event, stroke
Introduction
Atrial fibrillation (AF) is the most common 
supraventricular arrhythmia. Thromboembolic 
events, mainly involving cerebral circulation, 
constitute its most serious complication [1, 2]. In 
developed countries nearly 85% of strokes are of 
ischemic origin caused by a blockage of blood flow 
to the brain through narrowed or closed arteries, 
while 15% of strokes are hemorrhagic [3]. It has 
been established that AF is associated with a 5-fold 
increase in the risk of ischemic stroke and is gen-
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erally responsible for 15–20% of all strokes [4, 5]. 
A history of thromboembolism in a patient with 
AF is the strongest risk factor for another throm-
boembolic event [6]. Oral anticoagulants (OAC) 
should be used for prevention of thromboembolism 
among patients with AF and the risk factors for 
such events [7]. Non-vitamin K antagonist oral an-
ticoagulants (NOACs) are used increasingly more 
often and are characterized by at least a similar or 
greater effectiveness compared to that of vitamin 
K antagonists (VKA) [8–11]. 
The aim of this study was to assess the fre-
quency of use of NOACs among hospitalized pa-
tients with AF and a history of thromboembolism, 
as well as to analyze factors which predispose the 
choice of NOACs in this group of patients. 
Methods
Study group 
Patients with AF hospitalized at a reference 
cardiology center, over the years 2014–2017, 
were included in this retrospective analysis. The 
following inclusion criteria of the study were ap-
plied: diagnosis of AF at discharge from hospital, 
hospitalization not resulting in death. Patients with 
valvular AF (mechanical valve prosthesis, severe 
mitral stenosis) were excluded from the study. 
Thromboembolic complications were defined as: 
ischemic stroke, transient ischemic attack (TIA), 
and systemic embolism. Anticoagulation treatment 
was evaluated at discharge from the hospital. 
Statistical analysis
Arithmetic means, standard deviations, medi-
ans and quartiles were used to describe quantita-
tive data. Distribution of qualitative data was pre-
sented as frequency and percentages. Frequencies 
were compared using the c2 test or the exact Fisher 
test. Normality of distribution was tested with the 
Shapiro-Wilk test. If the assumption of normality 
of distribution was fulfilled, the distributions of 
quantitative variables were compared using the 
Student t-test, while in the absence of normality of 
distribution, the U Mann-Whitney test was applied. 
Uncorrected (crude) and corrected (adjusted) odds 
ratios (OR) together with 95% confidence intervals 
(CIs) were determined using a logistic regression 
model. Multivariate logistic regression analysis 
included variables with statistically significant OR, 
confirmed in univariate analysis. All statistical tests 
conducted were two-sided and zero hypotheses 
were rejected when p < 0.05. The R software v. 
3.4.3 (R Core Team (2017). R: A language and en-
vironment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria. URL 
https://www.R-project.org/) and STATISTICA v. 
12 were used to conduct the analyses. 
Results
In a group of 2834 consecutively hospitalized 
patients with AF, a history of thromboembolic 
complications was noted in 347 (12.2%) patients. 
Among the 347 patients with AF after thromboem-
bolic events, 245 (70.6%) patients were diagnosed 
with stroke, 56 (16.1%) patients with TIA, 37 
(10.7%) with systemic embolism, and more than 
one presentation of thromboembolic complication 
were noted in 9 (2.6%) patients. 
In the group of 347 patients examined with 
AF after thromboembolic event, 49.6% were male 
and mean patient age amounted to 75.1 years. 
Fifty-one (14.7%) patients were under 65 years 
of age, 104 (30%) patients were aged 65–74, 133 
(38.3%) patients were aged 75–84 years, and 59 
patients were at least 85 (17%). A 128 (36.9%) 
patients presented with paroxysmal AF, 48 (13.8%) 
patients with persistent AF, and 171 (49.3%) with 
permanent arrhythmia. In the study group of 347 
AF patients with a history of thromboembolic 
events, 322 (92.8%) received an OAC at the time 
of discharge from the hospital, including 133 on 
VKA (41.3% of patients treated with OAC) and 189 
on NOACs (58.7% of patients with OAC). Table 1 
presents pharmacological means of stroke preven-
tion in the study group. 
In a group of 189 patients treated with NOACs 
dabigatran was used most frequently — 116 
Table 1. Anti-stroke prophylaxis in patients with 
atrial fibrillation after thromboembolic complica-
tions (n = 347).
Type of prophylaxis Number and  
percentage  
of patients 
Oral anticoagulants 322 (92.8%)
Vitamin K antagonists 133 (38.3%)
Non-vitamin K oral anticoagulant: 189 (54.5%)
Apixaban 19 (5.5%)
Dabigatran 116 (33.4%)
Rivaroxaban 54 (15.6%)
Antiplatelet medicine / medicines 9 (2.6%)
Low molecular weight heparin 7 (2%)
Without prevention 9 (2.6%)
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patients (61.4% of subjects were treated with 
NOACs), followed by rivaroxaban — 54 (28.6% of 
subjects were treated with NOACs), and apixaban 
— 19 patients (10% of subjects were treated with 
NOACs). Standard doses were administered in 76 
(40.2%) patients on NOACs, while 113 (59.8%) 
patients received reduced doses. 
The following number of patients with AF and 
history of thromboembolic events were hospital-
ized during the years 2014–2017: 76, 86, 92, and 
68 patients, respectively. A significant increase in 
the proportion of patients on NOACs were among 
all OAC-treated subjects: from 34.2% in 2014 to 
75% of subjects in 2017 (Fig. 1). 
Patients with AF and a history of thrombo-
embolic events treated with VKA vs. NOACs 
with regard to age, type of AF, and comorbidities 
(Table 2) were compared. Patients with AF, who 
were prescribed a NOACs suffered from arterial 
hypertension heart failure, or myocardial infarc-
tion less often than those receiving VKA. They 
were also characterized by lower mean CHADS2 
and CHA2DS2VASc scores as well as higher left 
ventricular ejection fraction and smaller left atrial 
dimension in echocardiographic assessment. 
Univariate logistic regression analysis dem-
onstrated that among patients after thromboem-
bolic complications the following characteristics 
significantly reduced the chance of receiving 
a prescription for NOACs: arterial hypertension, 
heart failure, history of myocardial infarction, 
and CHADS2 score ≥ 4 points. Among echocar-
diographic parameters ejection fraction < 50% 
significantly reduced chance for the use of NOACs 
in the group studied. However, left atrial size 
≤ 40 mm was a factor significantly increasing the 
likelihood of being prescribed  NOACs (Table 3). 
Multivariate logistic regression analysis showed 
that arterial hypertension significantly reduced 
the chance of NOACs use, while left atrial size 
≤ 40 mm significantly increased the likelihood of 
NOACs administration in patients with AF and 
a history of thromboembolic events (Table 4). 
Discussion
In the present study, encompassing almost 
3000 hospitalized patients with AF, thromboem-
bolic events were diagnosed in 12% of subjects. In 
the PREFER registry thromboembolic complica-
tions were noted in 8.4% of patients with AF [12]. 
A similar proportion of patients with a history of 
stroke, amounting to 10.5%, was found in the 2nd 
phase of the GLORIA-AF registry [13]. A higher 
proportion of patients after stroke/TIA than in the 
current study was established in the GARFIELD 
registry — it amounted to 15.2% in cohort I, and 
21.4% in cohort II. In the Polish population of 
patients included in the GARFIELD registry the 
percentage of patients after stroke/TIA was lower 
and amounted to 8.3% and 7.9% in cohort I and II, 
respectively [14]. The population of patients in the 
present study was higher than in the GARFIELD 
registry — mean patient age was 75 years, while in 
the GARFIELD registry it amounted to 67 years in 
the Polish population; in the European population 
it amounted to 73 years in cohort II and 72 years in 
cohort I [14]. Among 2259 British patients with AF 
remaining under the care of general practitioners, 
19% had a history of stroke. Mean age of patients 
in this study was similar to that in the current 
study — 76 years [15]. 
Patients with a history of thromboembol-
ic complications have at least 2 points on the 
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Figure 1. Percentage of patients treated with vitamin K antagonist (VKA) and non-vitamin K antagonist oral anticoagu-
lants (NOAC) with atrial fibrillation after thromboembolic complications hospitalized between 2014 and 2017. 
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Table 2. Clinical characteristics of patients with atrial fibrillation vitamin K antagonist (VKA) or non-
vitamin K antagonist oral anticoagulant (NOAC)-treated after thromboembolic events.
Clinical feature OAC group (n = 322) VKA group (n = 133) NOAC group (n = 189) P
Age [years] 0.81
Mean ± SD 74.9 ± 9.9 74.8 ± 9.5 74.9 ± 10.9
Median (Q1–Q3) 76 (68–83) 76 (68–83) 76 (68–83)
Age [years] 0.61
Age < 50 3 (0.9%) 0 (0.0%) 3 (1.6%)
Age 50–64 45 (14.0%) 18 (13.5%) 27 (14.3%)
Age 65–74 99 (30.7%) 43 (32.3%) 56 (29.6%)
Age > 74 175 (54.3%) 72 (54.1%) 103 (54.5%)
Female 165 (51.2%) 71 (53.4%) 94 (49.7%) 0.52
Form of atrial fibrillation 0.59
Paroxysmal 161 (50.0%) 62 (46.6%) 99 (52.4%)
Persistent 116 (36.0%) 51 (38.4%) 65 (34.4%)
Permanent 45 (14.0%) 20 (15.0%) 25 (13.2%)
Medical history
Hypertension 258 (80.1%) 114 (85.7%) 144 (76.2%) 0.03
Heart failure 227 (70.5%) 106 (79.7%) 121 (64.0%) 0.002
Diabetes mellitus 115 (35.7%) 47 (35.3%) 68 (36.0%) 0.91
Previous stroke 234 (72.7%) 99 (74.4%) 135 (71.4%) 0.55
Previous TIA 60 (18.6%) 26 (19.5%) 34 (18.0%) 0.72
Coronary artery disease 101 (31.4%) 42 (31.6%) 59 (31.2%) 0.95
Myocardial infarction 91 (28.3%) 48 (36.1%) 43 (22.8%) 0.009
PCI 53 (16.5%) 27 (20.3%) 26 (13.8%) 0.12
CABG 31 (9.6%) 17 (12.8%) 14 (7.4%) 0.11
COPD 29 (9.0%) 13 (9.8%) 16 (8.5%) 0.69
Hyperthyroidism 21 (6.5%) 10 (7.5%) 11 (5.8%) 0.54
Hypothyroidism 31 (9.6%) 10 (7.5%) 21 (11.1%) 0.28
CHADS2 [points]
Mean ± SD 4.4 ± 1.0 4.5 ± 0.9 4.3 ± 1.0 0.04
Median (Q1–Q3) 4 (4–5) 5 (4–5) 4 (4–5)
CHADS2 2–3 58 (18%) 15 (11.3%) 43 (22.8%) 0.008
CHADS2 > 3 264 (82%) 118 (88.7%) 146 (77.2%) 0.008
CHA2DS2VASc [points]
Mean ± SD 6.5 ± 1.4 6.7 ± 1.3 6.4 ± 1.5 0.0 8
Median (Q1–Q3) 7 (6–7) 7 (6–8) 6 (5–7)
CHA2DS2VASc 2–3 9 (2.8%) 1 (0.8%) 8 (4.2%) 0.09
CHA2DS2VASc > 3 313 (97.2%) 132 (99.2%) 181 (95.8%) 0.09
HAS-BLED
Mean ± SD 2.6 ± 0.8 2.7 ± 0.7 2.6 ± 0.8
Median (Q1–Q3) 3 (2–3) 3 (2–3) 3 (2–3)
ECHOCARDIOGRAPHY 
EF [%] [n = 250] [n = 106] [n = 144] 0.04
Mean ± SD 46.9 ± 12.9 44.9 ± 13.7 48.4 ± 12.2
Median (Q1–Q3) 50 (40–55) 49,5 (38–55) 50 (43–55)
EF > 50% 101 (40.4%) 34 (32.1%) 56 (38.9%)
EF 50–30% 115 (46.0%) 54 (50.9%) 61 (42.4%)
EF < 30% 101 (13.6%) 34 (32.1%) 56 (38.9%)
Æ
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Table 2 (cont.). Clinical characteristics of patients with atrial fibrillation vitamin K antagonist (VKA) or 
non-vitamin K antagonist oral anticoagulant (NOAC)-treated after thromboembolic events.
Clinical feature OAC group (n = 322) VKA group (n = 133) NOAC group (n = 189) P
LA [mm] [n = 248] [n = 106] [n = 142] < 0.0001
Mean ± SD 47.3 ± 8.2 49.6 ± 8.9 45.7 ± 7.3
Median (Q1–Q3) 46 (42.5–52) 48.5 (45–54) 45 (41–50.7)
LA > 40 mm [n = 246] 205 (83.3%) [n = 106] 97 (91.5%) [n = 142] 108 (76.1%) 0.002
LABORATORY TESTS
Hemoglobin [g/dL] [n = 321] [n = 132] [n = 189] 0.38
Mean ± SD 13.2 ± 1.7 13.1 ± 1.7 13.2 ± 1.6
Median (Q1–Q3) 1.2 (12.1–14.3) 13.2 (12.1–14.2) 13.2 (12.1–14.5)
GFR [mL/min] 0.16
Mean ± SD 55.8 ± 18.6 53.7 ± 17.3 57.3 ± 19.4
Median (Q1–Q3) 54.9 (43.8–66.3) 53.7 (42.6–65.6) 56.0 (44.3–67.4)
GFR > 60 114 (35.4%) 43 (32.3%) 118 (37.6%) 0.43
GFR 60–46 111 (34,5%) 48 (36.1%) 63 (33.3%)
GFR 45–30 63 (19.6%) 25 (18.8%) 38 (20.1%)
GFR 29–15 23 (71%) 12 (9.0%) 11 (5.8%)
GFR < 15 1 (0.3%) 0 (0.0%) 1 (0.5%)
CABG — coronary artery bypass grafting; COPD — chronic obstructive pulmonary disease EF — ejection fraction; GFR — glomerular filtration 
rate; LA — left atrial; PCI — percutaneous coronary intervention; TIA — transient ischemic attack
Table 3. Factors increasing the chances of using non-vitamin K antagonist oral anticoagulant (NOAC) 
in patients with atrial fibrillation after thromboembolic complications — univariate logistic regression 
analysis.
Factors VKA group  
(n = 133)
NOAC group  
(n = 322)
Crude OR 95% CI P
Sex
Female 71 (53.4%) 94 (49.7%) Ref. level
Male 62 (46.6%) 95 (50.3%) 1.2 0.7–1.8 0.52
Age [years] 74.8 ± 9.5 74.9 ± 10.3 1.0 0.98–1.02 0.96
< 65 18 (13.5%) 30 (15.9%) Ref. level
65–74 43 (32.3%) 56 (29.6%) 0.8 0.4–1.6 0.49
 > 74 72 (54.1%) 103 (54.5%) 0.9 0.4–1.7 0.65
Form of AF
Paroxysmal 51 (38.3%) 65 (34.4%) Ref. level
Persistent 20 (15.0%) 25 (13.2%) 1.0 0.5–2.0 0.96
Permanent 62 (46.6%) 99 (52.4%) 1.3 0.8–2.0 0.36
Form of AF
Permanent 62 (46.6%) 99 (52.4%) Ref. level
Persistent 51 (38.3%) 65 (34.4%) 0.8 0.5–1.3 0.36
Paroxysmal 20 (15.0%) 25 (13.2%) 0.8 0.4–1.5 0.47
Hypertension
No 19 (14.3%) 45 (23.8%) Ref. level
Yes 114 (85.7%) 144 (76.2%) 0.5 0.30–0.96 0.04
Heart failure
No 27 (20.3%) 68 (36.0%) Ref. level 0.3–0.8 0.003
Yes 106 (79.7%) 121 (64.0%) 0.5
Æ
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Table 3 (cont.). Factors increasing the chances of using non-vitamin K antagonist oral anticoagulant (NOAC) 
in patients with atrial fibrillation after thromboembolic complications - univariate logistic regression analysis.
Factors VKA group  
(n = 133)
NOAC group  
(n = 322)
Crude OR 95% CI p
Diabetes mellitus
No 86 (64.7%) 121 (64.0%) Ref. level
Yes 47 (35.3%) 68 (36.0%) 1.0 0.6–1.6 0.91
Previous stroke
No 34 (25.6%) 54 (28.6%) Ref. level
Yes 99 (74.4%) 135 (71.4%) 0.9 0.5–1.4 0.55
Previous transient ischaemic attack
No 107 (80.5%) 155 (82.0%) Ref. level
Yes 26 (19.5%) 34 (18.0%) 0.9 0.5–1.6 0.72
Coronary artery disease
No 91 (68.4%) 130 (68.8%) Ref. level
Yes 42 (31.6%) 59 (31.2%) 1.0 0.6–1.6 0.95
Myocardial infarction
No 85 (63.9%) 146 (77.2%) Ref. level
Yes 48 (36.1%) 43 (22.8%) 0.5 0.3–0.9 0.009
Percutaneous coronary intervention
No 106 (79.7%) 163 (86.2%) Ref. level
Yes 27 (20.3%) 26 (13.8%) 0.6 0.3–1.1 0.12
Coronary artery bypass graft
No 116 (87.2%) 175 (92.6%) Ref. level
Yes 17 (12.8%) 14 (7.4%) 0.5 0.3–1.2 0.11
Chronic obstructive pulmonary disease
No 120 (90.2%) 173 (91.5%) Ref. level
Yes 13 (9.8%) 16 (8.5%) 0.9 0.4–1.8 0.69
CHADS2 score 4.5 ± 0.9 4.3 ± 1.0 0.8 0.6–0.97 0.029
2–3 15 (11.3%) 43 (22.8%) Ref. level
> 3 118 (88.7%) 146 (77.2%) 0.4 0.2–0.8 0.001
CHA2DS2VASC score 6.7 ± 1.3 6.4 ± 1.5 0.9 0.7–1.01 0.06
2–3 1 (0.8%) 8 (4.2%) Ref. level
> 3 132 (99.2%) 181 (95.8%) 0.2 0.02–1.4 0.10
HASBLED score 2.7 ± 0.8 2.6 ± 0.8 0.9 0.7–1.2 0.56
Ejection fraction [%] 44.9 ± 13.7 48.4 ± 12.2 1.02 1.001–1.04 0.037
Missing value 27 (20.3%) 45 (23.8%) –
> 50 34 (25.6%) 67 (35.4%) Ref. level
30–50% 54 (40.6%) 61 (32.3%) 0.6 0.3–0.995 0.048
< 30% 18 (13.5%) 16 (8.5%) 0.5 0.2–0.994 0.048
Left atrial group [mm] 49.6 ± 8.9 45.7 ± 7.3 0.94 0.91–0.97 0.0004
Missing value 27 (20.3%) 47 (24.9%) –
> 40 mm 97 (72.9%) 108 (57.1%) Ref. level
£ 40 mm 9 (6.8%) 34 (18.0%) 3.4 1.5–7.4 0.002
Hemoglobin [g/dL] 13.1 ± 1.7 13.2 ± 1.6 1.1 0.9–1.2 0.38
< 12 g/dL 31 (23.3%) 38 (20.1%) Ref. level
≥ 12 g/dL 101 (75.9%) 151 (79.9%) 1.2 0.7–2.1 0.47
GFR [mL/min] 53.7 ± 17.3 57.3 ± 19.4 1.01 0.998–1.023 0.09
> 60 mL/min 43 (32.3%) 71 (37.6%) Ref. level
60–46 mL/min 50 (37.6%) 66 (34.9%) 0.8 0.5–1.4 0.41
45–30 mL/min 26 (19.5%) 40 (21.2%) 0.9 0.5–1.7 0.82
< 30 mL/min 14 (10.5%) 12 (6.3%) 0.5 0.2–1.2 0.13
Data are shown as number (percentage) or mean ± standard deviation. CI — confidence interval; GFR — glomerular filtration rate; OR — odds 
ratio; VKA — vitamin K antagonist
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Table 4. Factors increasing the chances of  
using non-vitamin K antagonist oral anticoagulant 
in patients with atrial fibrillation after thrombo-
embolic complications — multivariate logistic 
regression analysis.
Factors Adjusted  
OR
95%  
CI
P
Hypertension
No Ref. level
Yes 0.4 0.2–0.9 0.04
Heart failure
No Ref. level
Yes 0.6 0.3–1.2 0.14
Myocardial infarction
No Ref. level
Yes 0.6 0.3–1.1 0.13
CHADS2 score
2–3 points Ref. level
> 3 points 1.0 0.4–2.7 0.97
Ejection fraction
> 50% Ref. level
50–30% 0.8 0.4–1.4 0.39
< 30% 0.8 0.3–1.8 0.53
Left atrial
> 40 mm Ref. level
£ 40 mm 2.5 1.1–5.8 0.03
CI — confidence interval; OR — odds ratio
CHA2DS2VASc scale, although usually the score is 
higher due to age and comorbidities. In the present 
study the majority of patients were over 75 years 
and mean CHA2DS2VASc of patients treated with 
OAC amounted to 6.5 points, thus this study group 
was at the highest risk of thromboembolic events. 
Lopatowska et al. [16] analyzed antithrombotic 
management in AF implemented into practice 
in a group of 1556 patients. The study showed 
that the use of OAC increased with increasing 
CHA2DS2VASc score but was less frequent in score 
≥ 4 irrespectively of whether it was primary or 
secondary prevention.
According to the current guidelines of the 
European Society of Cardiology (ESC) on the 
treatment of patients with AF, anticoagulation is 
indicated in men with at least 2 points and women 
with at least 3 points on the CHA2DS2VASc scale. 
Therefore, each patient who had suffered a throm-
boembolic complication of AF should receive an 
OAC [17]. Data from registries demonstrate that 
clinical practice differs significantly from the guide-
lines. It is estimated that half of patients with AF 
and no risk factors for thromboembolic complica-
tions receive an OAC and 1/3 of patients at high 
risk of thromboembolic events remain without 
prophylactic anticoagulation [18]. However, only 
about 10% with AF have absolute contraindica-
tions to anticoagulant treatment. Mazurek et al. 
[19] showed that in a group of 2250 patients with 
AF contraindications to OAC were present in 
only 8.3% of subjects. In the same study it was 
shown that among patients with AF at high risk 
of thromboembolic events both overtreatment, 
as well as undertreatment, were associated with 
significant increases in the risk of stroke, while 
undertreatment was also associated with increased 
total mortality [19]. In the present study OAC was 
administered in 93% of patients, which is in agree-
ment with the reports of other authors, who con-
firmed that contraindications to OAC are present in 
approximately one in ten patients with AF. In Dar-
lington Atrial Fibrillation Registry on 2259 patients 
with AF, a history of stroke was identified in 18.9% 
of subjects [20]. In this group of patients OAC in 
monotherapy or combined with an antiplatelet drug 
was applied in 61.7% of subjects, 1/3 of patients 
received only an antiplatelet drug, while 6.5% of 
subjects with AF and history of stroke had no anti-
coagulation therapy [20]. In the current study OAC 
was administered in 92.8% of patients with AF and 
history of stroke, an antiplatelet drug/drugs in 2.6% 
of subjects, low molecular weight heparin in 2%, 
and 2.6% of patients were left without prophylactic 
anticoagulation. In the present study the mean age 
of patients with AF after a thromboembolic event 
amounted to 75 years, while in a British study of 
patients after stroke it was 79.6%. Also, patients 
in the study herein were characterized by a higher 
mean CHA2DS2VASc score compared to that of the 
British authors. Significant differences regarding 
treatment of patients after thromboembolic compli-
cations in studies under comparison probably ensue 
from the fact that in the present study, prophylactic 
anticoagulation was implemented by a reference 
cardiac center, while in the British study, by general 
practitioners. 
In the current study the majority of patients on 
OAC were treated with NOACs. Reduced NOACs 
doses were used in 60% of patients and dabigatran 
was the most frequent therapeutic choice. In 
the SAMURAI-NVAF Study encompassing 1116 
patients after stroke/TIA discharged from neu-
rology centers, the majority of patients received 
VKA compared to NOAC (58.2 vs. 41.8%) [21]. 
Rivaroxaban, usually a full dose, was the most 
frequently chosen NOAC in the SAMURAI-NVAF 
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Study, followed by dabigatran and apixaban, which 
were most often used in reduced doses [21]. In 
the Novel Oral Anticoagulants in Stroke Patients 
(NOACISP)-LONGTERM registry that included 
251 patients after stroke, who were treated with an 
OAC, NOAC was administered in 78% of patients 
[22]. Over a 1-year observation period full adher-
ence was noted in 77.1% of patients treated with 
NOAC and 83.3% of patients receiving VKA [23]. 
The data on anticoagulant therapy in the group 
of women and men after thromboembolic compli-
cations is not consistent. In the present study, no 
significant differences were noted between the 
sexes preferring NOACs treatment. However, 
in the SAMURAI-NVAF study, the group of men 
after thromboembolism events were treated with 
NOACs more often than with VKA [21].
In the current study NOACs was prescribed 
more frequently than VKA in patients with lower 
thromboembolic risk according to the CHA2DS2- 
VASc and CHADS2 scales, as well as with non-
dilated left atrium, while VKA was used more 
often than NOACs among patients with arterial 
hypertension, heart failure, history of myocardial 
infarction and reduced left ventricular ejection 
fraction. Multivariate logistic regression analysis 
demonstrated that diagnosis of arterial hyperten-
sion significantly reduced the chance for NOACs 
administration for secondary prevention of stroke 
among patients with AF. It may be inferred that 
NOACs are more likely to be selected in lower-
risk patients with fewer comorbidities. In a study 
that included patients hospitalized over the years 
2004–2012 at the documented center, among 
patients at high risk of thromboembolic complica-
tions, the proportion of subjects with a history of 
thromboembolic events was higher in the group 
treated with OAC compared to those not treated 
with OAC [24]. In a Danish study conducted be-
tween 2011 and 2013, history of stroke was a factor 
predisposing the use of NOACs over VKA [25]. In 
the 2016 ESC guidelines experts recommend a 
preference of NOAC to VKA or acetylscalicylic acid 
among patients after stroke [17]. In the present 
study significant increase was demonstrated in the 
use of NOACs in patients after thromboembolic 
events — in 2017, ¾ of patients treated with oral 
anticoagulation received a NOACs. 
Limitations of the study
There are several limitations of the present 
study. As is the case for all retrospective studies, 
there exist potential unidentified confounders. Data 
sources could not ascertain symptom severity of 
AF and the date of thromboembolic complication. 
There was no adjustment for levels of socioeco-
nomic status or education levels of patients in the 
study group.
Conclusions
Oral anticoagulants were administered for 
secondary prevention of thromboembolic events 
in nearly all hospitalized patients with AF. NOACs 
were used in the majority of patients treated with 
oral anticoagulation and they were more often used 
in reduced than standard doses. NOACs were more 
frequently used for secondary prevention of stroke 
in AF patients with fewer comorbidities.
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